WO2004048331A1 - N-arylalkyl-3-aminoalcoxyindoles et leur utilisation en tant que ligands des recepteurs 5-ht - Google Patents

N-arylalkyl-3-aminoalcoxyindoles et leur utilisation en tant que ligands des recepteurs 5-ht Download PDF

Info

Publication number
WO2004048331A1
WO2004048331A1 PCT/IN2003/000371 IN0300371W WO2004048331A1 WO 2004048331 A1 WO2004048331 A1 WO 2004048331A1 IN 0300371 W IN0300371 W IN 0300371W WO 2004048331 A1 WO2004048331 A1 WO 2004048331A1
Authority
WO
WIPO (PCT)
Prior art keywords
indol
ethyl
dimethylamine
yloxy
methyl
Prior art date
Application number
PCT/IN2003/000371
Other languages
English (en)
Inventor
Venkata Satya Nirogi Ramakrishna
Vikas Shreekrishna Shirsath
Rama Sastri Kambhampati
Venkata Satya Veerabhadra Vadlamudi Rao
Venkateswarlu Jasti
Original Assignee
Suven Life Sciences Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Limited filed Critical Suven Life Sciences Limited
Priority to AU2003292508A priority Critical patent/AU2003292508A1/en
Publication of WO2004048331A1 publication Critical patent/WO2004048331A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/36—Oxygen atoms in position 3, e.g. adrenochrome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention includes compounds described by general formula (I), its stereoisomers, its radioisotopes, its geometric forms, its N-oxides, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, its useful bioactive metabolites and any suitable combination of the above.
  • the present invention also includes the processes for preparing such compounds of the general formula (I), its stereoisomers, its radioisotopes, its geometric forms, its N-oxides, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, its useful bioactive metabolites and also includes any suitable combination of the above.
  • the invention also describes various methods of administering these compounds of general formula (I), i.e. pharmaceutically acceptable dosage forms compositions and the use of such compounds and compositions in either therapy or diagnosis.
  • the compounds of the general formula (I) of this invention are 5-HT (Serotonin) ligands e.g. agonists or antagonists.
  • the compounds of the general formula (I) of this invention by the virtue of its chemical characteristic, could either independently or simultaneously modulate the melatonin receptor i.e. either these compounds are melatonergic ligands e.g. agonists or antagonists, or they interact with both 5-HT and/or as Melatonin receptors.
  • compounds of general formula (I) of this invention are useful for treating diseases wherein activity of either 5-HT (Serotonin) and/or Melatonin is modulated to obtain the desired therapeutic effect.
  • the compounds of this invention are useful in the treatment and / or prophylaxis of conditions such as psychosis, paraphrenia, psychotic depression, mania, schizophrenia, schizophreniform disorders, anxiety, migraine headache, depression, drug addiction, convulsive disorders, personality disorders, hypertension, autism, post-traumatic stress syndrome, alcoholism, panic attacks, obsessive-compulsive disorders, chronobiological abnormalities, circadian rhythms, anxiolytic, osteoporosis, ischemic stroke, lower the risk of SIDS in young infants with low endogenous melatonin levels, reproduction, glaucoma and sleep disorders.
  • the compounds of general formula (I) of this invention could also be useful in treating the psychotic, affective, vegetative and psychomotor symptoms of schizophrenia and the extrapyramidal motor side effects of other antipsychotic drugs; neurodegenerative disorders like Alzheimer's disease, Parkinson's and Huntington's chorea and chemotherapy-induced vomiting; and in modulation of eating behavior and thus are useful in reducing the morbidity and mortality associated with excess weight.
  • Many diseases of the central nervous system are influenced by the adrenergic, the dopaminergic and the serotoninergic neurotransmitter systems. Serotonin has been implicated in numerous diseases and conditions, which originate from central nervous system.
  • the list includes diseases and conditions related to sleeping, eating, perceiving pain, controlling body temperature, controlling blood pressure, depression, anxiety, schizophrenia and other bodily states.
  • Serotonin also plays an important role in the peripheral systems, such as the gastrointestinal system, where it has been found to mediate a variety of contractile, secretory and electrophysiologic effects.
  • the compounds which have receptor-specific agonism and/or antagonism for the treatment of a wide range of disorders including anxiety, depression, hypertension, migraine, obesity, compulsive disorders, schizophrenia, autism, certain other neurodegenerative disorders like Alzheimer, Parkinson, Huntington's chorea and chemotherapy-induced vomiting (References: Gershon M. D. et. al., 5-Hydroxytryptamine and enteric neurons. In: The Peripheral Actions of 5- Hydroxytryptamine, edited by J. R. Fozard. New York: Oxford, 1989, p. 247-273; Saxena P. R. et. al., Journal of Cardiovascular Pharmacology (1990), supplement 15, 17-34).
  • the major classes of serotonin receptors (5-HT ⁇ . 7 ) contain fourteen to eighteen separate receptors that have been formally classified (References: Glennon et al, Neuroscience and Behavioral Reviews (1990), 14, 35; and Hoyer D. et al, Pharmacol. Rev. (1994), 46, 157-203). Recently discovered information regarding sub-type identity, distribution, structure and function suggests that it is possible to identify novel, sub-type specific agents having improved therapeutic profiles with lesser side effects.
  • the 5-HT 6 receptor was identified in 1993 (References: Monsma et al, Mol. Pharmacol. (1993), 43, 320-327; and Ruat M. et al, Biochem. Biophys. Res. Com. (1993), 193, 269-276).
  • 5-HT 6 receptor has been linked to generalized stress and anxiety states (Reference: Yoshioka et al, Life Sciences (1998), 17/18, 1473-1477). Together these studies and observations suggest that the compound, which " antagonizes 5-HT 6 receptors, will be useful in treating various disorders of the central nervous system.
  • British Patent 2,035,310 refers to 3-aminoalkyl-1 H-indole-5-thioamides and carboxamides. The compounds are said to be useful in treating hypertension,
  • European Patent Publication 303,506 refers to 3-polyhydropyridyI-5- substituted-1 H-indoIes. The compounds are said to have 5-H ⁇ receptor agonists and vasoconstrictor activity and to be useful in treating migraine.
  • European Patent Publication 354,777 refers to N-piperidinylindolylethyl-alkane sulfonamide derivatives. The compounds are said to be 5-HTi receptor agonists and have vasoconstrictor activity and are useful in treating cephalic pain.
  • European Patent Publication 438,230 refers to indole-substituted five- membered heteroaromatic compounds. The compounds are said to have "5-HT like" receptor agonist activity and to be useful in the treatment of migraine and other disorders for which a selective agonist of these receptors is indicated.
  • European Patent Publication 313,397 refers to 5-heterocyclic indole derivatives. The compounds are said to have exceptional properties for the treatment and prophylaxis of migraine, cluster headache and headache associated with vascular disorders. These compounds are also said to have exceptional "5-HTrlike” receptor agonism.
  • International Patent Publication WO 91/18897 refers to 5-heterocyclic indole derivatives.
  • the compounds are said to have exceptional properties for the treatment and prophylaxis of migraine, cluster headache, and headache associated with vascular disorders. These compounds are also said to have exceptional "5-HTrlike" receptor agonism.
  • European Patent Publication 457,701 refers to aryloxy amine derivatives as having high affinity for 5-HTm serotonin receptors. These compounds are said to be useful for treating diseases related to serotonin receptor dysfunction, for example, migraine.
  • European Patent Publication 497,512 A2 refers to a class of imidazole, triazole and tetrazole derivatives that are selective agonists for "5-HT like" receptors. These compounds are said to be useful for treating migraine and associated disorders.
  • Schoeffter P. et al. refer to methyl 4- ⁇ 4-[4-(1 ,1,3-trioxo-2H-1 ,2-benzoisothiazol- 2-yl)butyl]-1-piperazinyl ⁇ 1 H-indole-3-carboxylate as a selective antagonist for the 5- HT I A receptor in their paper "SDZ216-525, a selective and potent 5-HTIA receptor antagonist" European Journal of Pharmacology, 244, 251-257 (1993).
  • the present invention relates to compounds of general formula (I), its stereoisomers, its radioisotopes, its geometric forms, its N-oxide, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, its useful bioactive metabolite and any suitable combination of the above.
  • the compounds of general formula (I) are as follows,
  • Ri, R 2 , R 3 , R , R 5 , R 6 , R , R 8 , R9, R 1 0, Rn and R 12 may be same or different, and represent hydrogen, halogen, perhaloalkyl, hydroxy, thio, amino, nitro, cyano, formyl, amidino, guanidino, substituted or unsubstituted groups selected from linear or branched (C C 12 )alkyl, (C 2 -C 12 )alkenyl, (C 2 -C 12 )alkynyl, (C 3 -C 7 )cycloalkyl, (C 3 - C 7 )cycloalkenyl, bicycloalkyl, bicycloalkenyl, (CrC ⁇ 2 )alkoxy, cyclo(C 3 -C 7 )alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroary
  • R 13 and R 1 represents hydrogen, alkyl, aryl, aralkyl or together with nitrogen atom form a cyclic three to seven membered ring, optionally, R 1 3 and R 14 together may form a part of cyclic structure along with the intervening nitrogen;
  • the heterocycle may have either one, two or three double bonds; optionally it may also contain one to three heteroatom selected from the group of oxygen, nitrogen and sulfur, and includes ring fused with any carbocyclic or heterocyclic ring, which can be saturated or unsaturated; optionally, Rn and R 13 together may form a part of cyclic structure along with the intervening nitrogen and carbon atoms;
  • the heterocycle may have either one, two or three double bonds; optionally it may also contain one to three heteroatom selected from the group of oxygen, nitrogen and sulfur, and includes ring fused with any carbocyclic or heterocyclic ring, which can be saturated or unsaturated;
  • A represents one or two hydrogens, oxygen, hydroxy, lower(CrC 6 )alkyl or lower(C C 6 ) alkoxy;
  • R ⁇ 4 are methyl or ethyl; then A is never -(H) 2 and also includes the salts of such compounds.
  • Partial list of such compounds of general formula (!) is as follows: [2-(1-(Benzoyl)-1H-indol-3-yloxy)ethyl]dimethylamine ; [2-(1-(2'-Bromobenzoyl)-1H-indol-3-yloxy)ethyl]dimethyIamine ; [2-(1-(Benzyl)-1 H-indol-3-yloxy)ethyl]dimethylamine ; [2-(1-(2'-Bromobenzyl)-1W-indol-3-yloxy)ethyl]dimethylamine ; [2-(1-(Benzoyl)-2-phenyl-1/-/-indol-3-yloxy)ethyl]dimethylamine ; [2-(1-(2'-B
  • the present invention also relates to the process for preparing the compound of the general formula (I) its stereoisomers, its radioisotopes, its geometric forms, its
  • the present invention also relates to the stereoisomers, which as a rule are obtained as racemates that can be separated into the optically active isomers in a manner known per se.
  • the present invention also relates to radio-labeled isotopes, which are identical to those defined in the general formula (I), but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number found usually in nature.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine, iodine, bromine and mTecnitium, exemplified by 2 H, 3 H, 1 C, 13 C, 4 C, 13 N, 15 N, 5 0, 18 F, 99m Tc, 31 P, S, 123 l and 125 l.
  • the nitrogen mono-oxides may exist as a single positional isomer or a mixture of 2° positional isomers (e.g., a mixture of 1-N-oxide and 4-N-oxide piperazine or a mixture of 1-N-oxide and 4-N-oxide piperazines).
  • Suitable pharmaceutically acceptable acid addition salts of compounds of the general formula (I) can be prepared of the aforementioned base compounds of this invention are those which form non-toxic acid addition salts, includes, salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benezenesulfonate, p- tolunesulfonate, palmoate and oxalate.
  • pharmacologically acceptable anions such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate,
  • Suitable pharmaceutically acceptable base addition salts of compounds of the general formula (I) can be prepared of the aforementioned acid compounds of this invention are those which form non-toxic base addition salts, includes, salts containing pharmaceutically acceptable cations, such as Lithium, sodium, potassium, calcium and magnesium, salts of organic bases such as lysine, arginine, guanidine, diethanolamine, choline, tromethamine and the like; ammonium or substituted ammonium salts.
  • salts of the compound of formula (I) can be obtained by converting derivatives which have tertiary amino groups into the corresponding quarternary ammonium salts in the methods known in the literature by using quarternizing agents.
  • Possible quartemizing agents are, for example, alkyl halides such as methyl iodide, ethyl bromide and n-propyl chloride, including arylalkyl halides such as benzyl chloride or 2-phenylethyl bromide.
  • other salts are included in the invention. They may serve as intermediates in the purification of the compounds, in the preparation of other salts, or in the identification and characterization of the compounds or intermediates.
  • the pharmaceutically acceptable salts of compounds of formula (I) may exists as solvates, such as with water, methanol, ethanol, dimethylformamide, ethyl acetate, and the like. Mixtures of such solvates can also be prepared.
  • the source of such solvate can be from the solvent of crystallization, inherent in the solvent preparation or crystallization, or adventitious to such solvent. Such solvates are within the scope of this invention.
  • a prodrug is a drug which has been chemically modified and may be biologically in-active at the site of action, but which may be degraded or modified by one or more enzymatic or other in-vivo processes to the parent form.
  • This prodrug should have a different pharmacokinetic profile than the parent, enabling easier absorption across the mucosal epithelium, better salt formation, or solubility, and/or improved systemic stability (an increase in the plasma half-life, for example).
  • chemical modifications include the following:
  • ester or amide derivatives which may be cleaved by esterases or lipases;
  • Another aspect of the present invention comprises of a pharmaceutical composition, containing at least one of the compounds of the general formula (I), their derivatives, their analogs, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates thereof as an active ingredient, together with pharmaceutically employed carriers, auxiliaries and the like.
  • An effective amount of a compound of general formula (I) or its salt is used for producing medicaments of the present invention, along with conventional pharmaceutical auxiliaries, carriers and additives.
  • the present invention also relates to the pharmaceutically acceptable compositions containing them, and the use of these compounds and compositions in medicine.
  • the compounds of general formula (I) of this invention are useful in the treatment and/ or prophylaxis of a condition wherein modulation of 5-HT activity is desired.
  • the compounds of general formula (I) of this invention are useful in the treatment and/ or prophylaxis of a condition wherein modulation of melatonin activity is desired.
  • the compounds of general formula (I) of this invention are useful in the treatment and/ or prophylaxis of a condition wherein modulation of 5-HT and melatonin activities gives desired effect.
  • the present invention provides for use of the compounds of general formula (I) according to above, for the manufacture of the medicaments for the potential use in the treatment and/ or prophylaxis of certain CNS disorders such as, anxiety, depression, convulsive disorders, obsessive-compulsive disorders, migraine headache, cognitive memory disorders e.g.
  • ADHD Alzheimer's disease and age-related cognitive decline
  • personality disorders personality disorders, psychosis, paraphrenia, psychotic depression, mania, schizophrenia, schizophreniform disorders, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, panic attacks, chronobiological abnormalities, circadian rhythms, anxiolytic, osteoporosis, ischemic stroke, lower the risk of SIDS in young infants with low endogenous melatonin levels, reproduction, glaucoma, sleep disorders (including disturbances of Circadian rhythm) and also disorders associated with spinal trauma and / or head injury such as hydrocephalus.
  • Compounds of the invention are further expected to be of use in the treatment of mild cognitive impairment and other neurodegenerative disorders like Alzheimer's disease, Parkinson's and Huntington's chorea.
  • the compounds of the invention are also expected to be of use in the treatment of certain Gl (Gastrointestinal) disorders such as IBS (Irritable bowel syndrome) or chemotherapy induced emesis.
  • the compounds of the invention are also expected to be of use in the modulation of eating behavior and these compounds can also be used to reduce morbidity and mortality associated with the excess weight.
  • the present invention provides a method for the treatment of a human or a animal subject suffering from certain CNS disorders such as, anxiety, depression, convulsive disorders, obsessive-compulsive disorders, migraine headache, cognitive memory disorders e.g ; Alzheimer's disease and age-related cognitive decline, ADHD (Attention Deficient Hyperactivity Disorder), personality disorders, psychosis, paraphrenia, psychotic depression, mania, schizophrenia, schizophreniform disorders, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, panic attacks, chronobiological abnormalities, circadian rhythms, anxiolytic, osteoporosis, ischemic stroke, lower the risk of SIDS in young infants with low endogenous melatonin levels, reproduction, glaucoma, sleep disorders (including disturbances of Circadian rhythm) and also disorders associated with spinal trauma and /or head injury such as hydrocephalus.
  • CNS disorders such as, anxiety, depression, convulsive disorders, obsessive-compul
  • Compounds of the invention are further expected to be of use in the treatment of mild cognitive impairment and other neurodegenerative disorders like Alzheimer's disease, Parkinson's and Huntington's chorea.
  • the present invention also provides a method for modulating 5-HT and/ or melatonin receptor function desired in certain cases.
  • Compounds of the present invention may be administered in combination with other pharmaceutical agents, such as apo-B/MTP inhibitors, MCR-4 agonists, CCK-A agonists, monoamine reuptake inhibitors, sympathomimetic agents, adrenergic receptor agonists, dopamine agonists, meianocyte-stimulating hormone receptor analogs, cannabinoid 1 receptor antagonists, melanin concentrating hormone antagonists, leptins, leptin analogs, leptin receptor agonists, galanin antagonists, lipase inhibitors, bombesin agonists, neuropeptide-Y antagonists, thyromimetic agents, dehydroepiandrosterone or analogs thereof, glucocorticoid receptor agonists or antagonists, orexin receptor antagonists, urocortin binding protein antagonists, glucagon-like peptide-1 receptor agonists, ciliary neurotrophic factors, AGRPs (human agouti-related proteins),
  • phrases "pharmaceutically acceptable” indicates that the substance or composition must be compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.
  • the terms “treating”, “treat”, or “treatment” embrace both preventative, i.e., prophylactic, and palliative treatment.
  • compound of the present invention refers to compounds of Formulae (I), nitrogen oxides thereof, prodrugs of the compounds or nitrogen oxides, pharmaceutically acceptable salts of the compounds, nitrogen oxides, and/or prodrugs, and hydrates or solvates of the compounds, nitrogen oxides, salts, is and/or prodrugs, as well as, all stereoisomers (including diastereoisomers and enantiomers), tautomers and isotopically labeled compounds.
  • the present invention also relates to the novel intermediates, represented by general formulae (II), (IV), (VI), (VII), (IX) and (X), their stereoisomers, their radioisotopes, their geometric forms, their N-oxide, their salts, their solvates and any suitable combination of above, involved in preparing the compounds of general formula (I) and the process of preparation of such intermediates.
  • novel intermediates represented by general formulae (II), (IV), (VI), (VII), (IX) and (X), their stereoisomers, their radioisotopes, their geometric forms, their N-oxide, their salts, their solvates and any suitable combination of above, involved in preparing the compounds of general formula (I) and the process of preparation of such intermediates.
  • the present invention relates to compounds of general formula (I), their stereoisomers, its radioisotopes, their geometric forms, their N-oxides, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and any suitable combination of above.
  • the present invention relates to compounds of general formula (I), described as follows,
  • Ri, R 2 , R 3 , R 4 , R5, Re, R7, Re, R9, R10, Rn and R 12 may be same or different, and represent hydrogen, halogen, perhaloalkyl, hydroxy, thio, amino, nitro, cyano, formyl, amidino, guanidino, substituted or unsubstituted groups selected from linear or branched (C C 12 )alkyl, (C 2 -C 2 )alkenyl, (C 2 -C 12 )alkynyl, (C 3 -C 7 )cycloalkyl, (C 3 - C 7 )cycloalkenyl, bicycloalkyl, bicycloalkenyl, (CrC ⁇ 2 )aIkoxy, cyclo(C- 3 -C 7 )alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaryl, hetero
  • R 1 3 and R represents hydrogen, alkyl, aryl, aralkyl or together with nitrogen atom form a cyclic three to seven membered ring, optionally, R 1 3 and R ⁇ together may form a part of cyclic structure along with the intervening nitrogen;
  • the heterocycle may have either one, two or three double bonds; optionally it may also contain one to three heteroatom selected from the group of oxygen, nitrogen and sulfur, and includes ring fused with any carbocyclic or heterocyclic ring, which can be saturated or unsaturated; optionally, Rn and R 13 together may form a part of cyclic structure along with the intervening nitrogen and carbon atoms;
  • the heterocycle may have either one, two or three double bonds; optionally it may also contain one to three heteroatom selected from the group of oxygen, nitrogen and sulfur, and includes ring fused with any carbocyclic or heterocyclic ring, which can be saturated or unsaturated.
  • "A" represents one or two hydrogens, oxygen, hydroxy or lower(C C 6
  • R 1t R 2 , R 3 , R 4 and R 0 are together hydrogens then R 13 and R ⁇ 4 are methyl or ethyl; then A is never -(H) 2 and also includes the salts of such compounds.
  • R 12 wherever applicable may be selected from halogen atom such as fluorine, chlorine, bromine or iodine; perhaloalkyl particularly perhalo(CrC 6 )alkyl such as fluoromethyl, difluoromethyl, trifluoromethyl, trifluoroethyl, fluoroethyl, difluoroethyl and the like; substituted or unsubstituted (C
  • Suitable cyclic structures formed by the two adjacent groups like Ri and R 2 or R 2 and R 3 or R 3 and R or R5 and R 6 or R 6 and R 7 or R 7 and R 8 or R 8 and Rg or Rn and R 1 together with the carbon atoms to which they are attached contain 5 to 6 ring atoms which may optionally contain one or more heteroatoms selected from oxygen, nitrogen or sulfur and optionally contain one or more double bonds and optionally contain combination of double bond and hetero atoms as described earlier.
  • the cyclic structures may be optionally substituted phenyl, naphthyl, pyridyl, furanyl, thienyl, pyrrolyl, imidazolyl, pyrimidinyl, pyrazinyl and the like.
  • Suitable substituents on the cyclic structure formed by R-i and R 2 or R 2 and R 3 or R 3 and R 4 or R 5 and R 6 or R 6 and R 7 or R 7 and R 8 or R 8 and Rg or Rn and R 12 together with the adjacent carbon atoms to which they are attached include oxo, hydroxy, halogen atom such as chlorine, bromine and iodine; nitro, cyano, amino, formyl, (CrC 3 )alkyl, (C C 3 )alkoxy, thioalkyl, alkylthio phenyl or benzyl groups.
  • R 1 3 and R 14 preferably represents hydrogen, substituted or unsubstituted linear or branched (C C 12 )alkyl like methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, pentyl, hexyl, octyl and the like; aryl group such as phenyl or naphthyl, the aryl group may be substituted; cyclo(C 3 -C 7 )alkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, the cycloalkyl group may be substituted; the aralkyl group may be substituted and the substituted aralkyl is a group such as CH 3 C 6 H 4 CH 2 , Hal-C 6 H 4 CH 2 , CH 3 OC 6 H 4 CH 2 , CH 3 OC 6 H 4 CH 2
  • Suitable hetero cyclic rings formed by either Rn and R 13 or R 1 and R ⁇ 4 be selected from pyrrolyl, imidazolyl, pyrimidinyl, pyrazinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxazolinyl, diazolinyl and the like, the heterocyclyl group may be substituted; heteroaryl group such as pyridyl, pyrrolyl, oxazolyl, imidazolyl, oxadiazolyl, tetrazolyl, benzopyranyl and the like, the heteroaryl group may be substituted; heterocyclo(CrC 6 )alkyl, such as pyrrolidinealkyl, piperidinealkyl, morpholinealkyl, thiomorpholinealkyl, oxazolinealkyl and the like, the heterocyc!o(Cr C ⁇ jalkyl group may be
  • Compounds of the present invention may be synthesized by synthetic routes that include processes analogous to those known in the chemical arts, particularly in light of the description contained herein.
  • the starting materials are generally available from commercial sources such as Aldrich Chemicals (Milwaukee, Wl) or are readily prepared using methods well known to those skilled in the art (e.g., prepared by methods generally described in Louis F. Fieser and Mary Fieser, Reagents for Organic Synthesis, v. 1-1 9, Wiley, New York (1 967-1999 ed.), or Beilsteins Handbuch der organischen Chemie, 4, Aufl. ed. Springer-Veriag, Berlin, including supplements (also available via the Beilstein online database)).
  • reaction schemes depicted below provide potential routes for synthesizing the compounds of the present invention as well as key intermediates. For a more detailed description of the individual reaction steps, see the Examples section. Those skilled in the art will appreciate that other synthetic routes may be used to synthesize the inventive compounds. Although specific starting materials and reagents are depicted in the schemes and discussed below, other starting materials and reagents can be easily substituted to provide a variety of derivatives and/or reaction conditions. In addition, many of the compounds prepared by the methods described below can be further modified in light of this disclosure using conventional chemistry well known to those skilled in the art.
  • Suitable substituents for -Lg are for example, a halogeno, for example a chloro, bromo, iodo, or aryl or alkyl sulfonyloxy group, for example, a methanesulfonyloxy or toluene-4-sulfonyloxy group or trifluoroacetate.
  • a halogeno for example a chloro, bromo, iodo, or aryl or alkyl sulfonyloxy group, for example, a methanesulfonyloxy or toluene-4-sulfonyloxy group or trifluoroacetate.
  • Suitable amino-protecting groups include acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBz) and Fluorenylmethyleneoxycarbonyl (Fmoc).
  • Fmoc Fluorenylmethyleneoxycarbonyl
  • the present invention also provides processes for preparing compounds of general formula (I) as defined above their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and novel intermediates involved therein, which are as described below.
  • processes for preparing compounds of general formula (I) as defined above their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and novel intermediates involved therein which are as described below.
  • R 1 ( R 2 , R 3 , R , and Rio are as defined in relation to formula (I), further Rio could be protected form thereof;
  • R represents either of a suitable N-protecting group, or a group such as,
  • the above reaction is preferably carried out in a solvent such as THF, toluene, acetone, ethyl acetate, DMF, DMSO, DME, N-methylpyrrolidone, methanol, ethanol propanol and the like and preferably using either acetone or DMF.
  • a solvent such as THF, toluene, acetone, ethyl acetate, DMF, DMSO, DME, N-methylpyrrolidone, methanol, ethanol propanol and the like and preferably using either acetone or DMF.
  • the inert atmosphere may be maintained by using inert gases such as N 2 , Ar or He.
  • the reaction may be affected in the presence of a base such as K 2 C0 3 , NaOH, Na 2 C ⁇ 3 ,
  • reaction mixture is generally heated to an elevated temperature or reflux temperature of the solvent, until the reaction is complete.
  • basic agents can be used in this condensation.
  • preferred basic agents are amines, such as trimethylamine, triethylamine, tributylamine, N-methylmorpholine, piperidine, N-methylpiperidine, pyridine and 4- (N,N- dimethyIamino)pyridine, with a preferred basic agent being K 2 C0 3 .
  • Reaction times of about 30 minutes to 72 hours are common.
  • the reaction mixture can be optionally acidified before workup.
  • the product can be isolated by precipitation, washed, dried and further purified by standard methods such as recrystallization, column chromatography etc.
  • step (i) and (ii) can be carried out using conventional methods. These will depend upon the precise nature of the substituents R , R 2 , R 3 , R 4 , R o, Rn, R ⁇ 2 , R 13 , and R ⁇ in each case. Examples of suitable reactions are illustrated hereinafter. Scheme 2:
  • compounds of formula (I) may be prepared by reacting a compound of formula (IV) given below,
  • Suitable bases are, generally, inorganic compounds such as alkali metal hydroxides and alkaline earth metal hydroxides, such as lithium hydroxide, sodium hydroxide, potassium hydroxide and calcium hydroxide; alkali metal oxides and alkaline earth metal oxides, lithium oxide, sodium oxide, magnesium oxide and calcium oxide; alkali metal hydrides and alkaline earth metal hydrides such as lithium hydride, sodium hydride, potassium hydride and calcium hydride; alkali metal amides and alkaline earth metal amides such as lithium amide, sodium amide, potassium amide and calcium amide; alkali metal carbonates and alkaline earth metal carbonates such as lithium carbonate and calcium carbonate; and also alkali metal hydrogen carbonates and alkaline earth metal hydrogen carbonates such as sodium hydrogen carbonate; organometallic compounds, particularly alkali-metal alkyls
  • reaction may be effected in the presence of phase transfer catalyst such as tetra-n-butylammonium hydrogensulphate and the like.
  • phase transfer catalyst such as tetra-n-butylammonium hydrogensulphate and the like.
  • the inert atmosphere may be maintained by using inert gases such as N 2 , Ar or He. Reaction times may vary from 1 to 24 hrs, preferably from 2 to 6 hours, whereafter, if desired, the resulting compound is continued into a salt thereof.
  • compounds of formula (I) may be prepared by reacting a compound of formula (VI)
  • R 1t R 2 , R 3 , R and R 0 are as defined in relation to formula (I), R 10 could also be protected form thereof;
  • R a is defined as either hydrogen, halogen (such as chloro or bromo), lithio, trimethylsilyl, lower alkoxy, boronic acid or trifluoromethanesulfonate groups;
  • R is defined as a suitable N-protecting group or a group such as,
  • n, Rn, R ⁇ 2 , R 13 , and R 4 are as defined in relation to compound of formula (I) or precursor thereof and Lg is a leaving group; and thereafter if desired or necessary carrying out additional steps described above.
  • Suitable substituents for Lg are hydroxy, sulfonyloxy group or a halogeno as defined earlier and the selection is based upon the nature of substitution at R a .
  • the above reaction is preferably carried out in a solvent such as THF, toluene, ethyl acetate, acetone, water, DMF, DMSO, DME, and the like or a mixture thereof, and preferably using either acetone or DMF.
  • a solvent such as THF, toluene, ethyl acetate, acetone, water, DMF, DMSO, DME, and the like or a mixture thereof, and preferably using either acetone or DMF.
  • the inert atmosphere may be maintained by using inert gases such as N 2 , Ar or He.
  • the reaction may be affected in the presence of a base such as K 2 C0 3 , Na 2 C0 3 , NaH or mixtures thereof.
  • the reaction temperature may range from 20 °C to 150 °C based on the choice of solvent and preferably at a temperature in the range from 30 °C to 100 °C.
  • the duration of the reaction may range from 1 to 24 hours,
  • compounds of formula (I) may be prepared by reacting a compound of formula (VII),
  • n, Ri, R 2 , R 3 , R 4 , Rs, Re, R7, Rs, R9, Rn, R 12 and A are as defined in relation to formula (I); or R 1 0 is also a protected form thereof; with a compound of formula (VIII)
  • Suitable values for Lg are for example, a halogeno or sulfonyloxy group, for example a chloro, bromo, iodo, methanesulfonyloxy or toluene-4-sulfonyloxy group or trifluoroacetyl.
  • compounds of formula (I) may be prepared by reductive alkylation of compounds of formula (IX)
  • R ⁇ 0 could also be a protected form thereof;
  • R is defined as a suitable N-protecting group or a group such as, where A, R 5 , Re, R7, Rs and Rg are as defined earlier for compound of formula (I); by reductively alkylating a compound of formula (VIII) or its acid addition salt ,
  • NR 13 R ⁇ 4 H (VIII) wherein R ⁇ 3 and R ⁇ are as defined in relation to compound of formula (I) or precursor thereof; and thereafter if desired or necessary carrying out additional steps described above.
  • the reaction may be performed in a solvent such as methanol or ethanol in the presence of hydrogen and a suitable catalyst such as palladium on carbon, sodium cyanoborohydride/acetic acid.
  • . 6 alkyl, a cycloalkyl containing 3-8 carbon atoms or a benzyl radical in which phenyl ring is substituted and R ⁇ 4 is hydrogen may be prepared from another compound of formula (X)
  • Rm is a group R 1 0 as defined in relation to formula (I) or protected form thereof; and in which R b represents hydrogen atom or a benzyl group in which phenyl ring is substituted and is removable by hydrogenolysis, R is defined as a suitable N-protecting group or a group such as, where A, R 5 , R 6 , R7, R 8 and Rg are as defined earlier for compound of formula (I), with a compound of formula (XI) 13
  • R 10 , R 13 and R 14 represents hydrogen atoms
  • these compounds may be prepared according to this invention by hydrogenolysing the corresponding indole derivative, in which above substituents represent one or more benzyl groups removable by hydrogenolysis.
  • indole derivatives of the general formula (I) in which R 1 3 is benzyl or a substituted benzyl group removable by hydrogenolysis and R M is hydrogen may according to this invention be prepared by partially hydrogenolysing the corresponding indole derivative in which R ⁇ 4 is identical to the substituent R u above.
  • the said hydrogenolysis is performed in a solvent such as ethanol in the presence of a suitable catalyst, e.g. palladium on carbon.
  • the reaction is performed in a solvent such as methanol or ethanol in the presence of hydrogen and a suitable catalyst such as palladium on carbon.
  • R-i, R 2 , R 3 , R 4 , R5, Re, R7, Rs, R9 and Rm may be same or different, and represent hydrogen, halogen, perhaloalkyl, hydroxy, thio, amino, nitro, cyano, formyl, amidino, guanidino, substituted or unsubstituted groups selected from linear or branched (CrC 12 )alkyl, (C 2 -C 2 )alkenyl, (C 2 -C 12 )alkynyl, (C 3 -C 7 )cycloalkyl, (C 3 - C 7 )cycloalkenyl, bicycloalkyl, bicycloalkenyl, (CrC ⁇ 2 )alkoxy, cyclo(C 3 -C 7 )alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heterocyclylalkyl, hetero
  • Ri, R 2 , R 3 , R 4 , R and R 2 may be same or different, and represent hydrogen, halogen, perhaloalkyl, hydroxy, thio, amino, nitro, cyano, formyl, amidino, guanidino, substituted or unsubstituted groups selected from linear or branched (CrC ⁇ 2 )alkyl, (C 2 - C 12 )alkenyl, (C 2 -C ⁇ 2 )alkynyl, (C 3 -C 7 )cycloalkyl, (C 3 -C 7 )cycloalkenyl, bicycloalkyl, bicycloalkenyl, (CrC 2 )aIkoxy, cyclo(C 3 -C 7 )a!koxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heterocyclylalkyl, heteroaralkyl, heteroaryl,
  • Rm represents hydrogen, formyl, substituted or unsubstituted groups selected from linear or branched (CrC ⁇ 2 )alkyl, (C 2 -C ⁇ 2 )alkenyl, (C 2 -C 2 )alkynyl, (C 3 - C 7 )cycloalkyl, (C 3 -C )cycloalkenyl, bicycloalkyl, bicycloalkenyl, (CrC ⁇ 2 )alkoxy, cyclo(C 3 -C 7 )alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heterocyclylalkyl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, heterocyclylalkyloxy, acyl, acyloxy, acylamino, monoalkylamino, dialkylamino, arylamino, diarylamino, aralkylamino, hydroxy
  • Rm and R ⁇ 4 represents hydrogen, alkyl, aryl, aralkyl or together with nitrogen atom form a cyclic three to seven membered ring, optionally, Rm and R ⁇ 4 together may form a part of cyclic structure along with the intervening nitrogen;
  • the heterocycle may have either one, two or three double bonds; optionally it may also contain one to three heteroatom selected from the group of oxygen, nitrogen and sulfur, and includes ring fused with any carbocyclic or heterocyclic ring, which can be saturated or unsaturated; optionally, R and R 13 together may form a part of cyclic structure along with the intervening nitrogen and carbon atoms;
  • the heterocycle may have either one, two or three double bonds; optionally it may also contain one to three heteroatom selected from the group of oxygen, nitrogen and sulfur, and includes ring fused with any carbocyclic or heterocyclic ring, which can be saturated or unsaturated; and
  • "n" is an integer ranging from 1 to 8, preferably 1 to 4, wherein
  • Ri, R 2 , R 3 , R , Rs, Re, R7, Rs, R9 and Rm may be same or different, and represent hydrogen, halogen, perhaloalkyl, hydroxy, thio, amino, nitro, cyano, formyl, amidino, guanidino, substituted or unsubstituted groups selected from linear or branched (C C 12 )alkyl, (C 2 -C 2 )alkenyl, (C 2 -C ⁇ 2 ) alkynyl, (C 3 -C 7 )cycloalkyl, (C 3 - C 7 )cycloalkenyl, bicycloalkyl, bicycloalkenyl, (C C 12 )alkoxy, cyclo(C 3 -C 7 )alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heterocyclylalkyl, heteroaralkyl, heteroaral
  • Ri, R 2 , R 3 , R , R 5 , R 6 , R 7 , R 8 , Rg, Rm, Rn and R 2 may be same or different, and represent hydrogen, halogen, perhaloalkyl, hydroxy, thio, amino, nitro, cyano, formyl, amidino, guanidino, substituted or unsubstituted groups selected from linear or branched (C r C ⁇ 2 )alkyl, (C 2 -C 2 )alkenyl, (C 2 -C 2 )alkynyl, (C 3 -C 7 )cycloalkyl, (C 3 - C 7 )cycloalkenyl, bicycloalkyl, bicycloalkenyl, (C C 12 )alkoxy, cyclo(C 3 -C 7 )alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroary
  • Ri, R 2 , R 3 , R 4 , R 5 , Re, R7, Rs, R9, Rm, Rn and R ⁇ 2 may be same or different, and represent hydrogen, halogen, perhaloalkyl, hydroxy, thio, amino, nitro, cyano, formyl, amidino, guanidino, substituted or unsubstituted groups selected from linear or branched (C C 12 )alkyl, (C 2 -C 12 )alkenyl, (C 2 -C ⁇ 2 )alkynyl, (C 3 -C )cycloalkyl, (C 3 - C 7 )cycloalkenyl, bicycloalkyl, bicycloalkenyl, (CrC ⁇ 2 )alkoxy, cyclo(C 3 -C 7 )alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heterocyclylall
  • R N-protecting group
  • R t R 2 , R 3 , R 4 , R5, Re, R7, Rs, R9, R10, Rn and R ⁇ 2 may be same or different, and represent hydrogen, halogen, perhaloalkyl, hydroxy, thio, amino, nitro, cyano, formyl, amidino, guanidino, substituted or unsubstituted groups selected from linear or branched (CrC 12 )alkyl, (C 2 -C 12 )alkenyl, (C 2 -C 12 )alkynyl, (C 3 -C 7 )cycloalkyl, (C 3 - C )cycloalkenyl, bicycloalkyl, bicycloalkenyl, (C C ⁇ 2 )alkoxy, cyclo(C 3 -C 7 )alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heterocyclyl, heterocycly
  • Procedure to prepare compounds of formula (X) is as reported in GB patent 1,306,230.
  • the process includes hydrogenolysis of compounds of formula (I) wherein Rm and/or R M are benzyl groups or hydrogens according to the method known in the art.
  • stereoisomers of compounds of general formula (I) may be prepared by one or more ways presented below: i) One or more of the reagents may be used in their optically active form. ii) Optically pure catalyst or chiral ligands along with metal catalyst may be employed in the reduction process. The metal catalysts may be employed in the reduction process. The metal catalyst may be Rhodium, Ruthenium, Indium and the like. The chiral ligands may preferably be chiral phosphines (Principles of Asymmetric synthesis, J. E. Baldwin Ed., Tetrahedron series, 14, 311-316).
  • the mixture of stereoisomers may be resolved by conventional methods such as forming a diastereomeric salts with chiral acids or chiral amines, or chiral amino alcohols, chiral amino acids.
  • the resulting mixture of diastereomers may then be separated by methods such as fractional crystallization, chromatography and the like, which is followed by an additional step of isolating the optically active product by hydrolyzing the derivative (Jacques et. al., "Enantiomers, Racemates and Resolution", Wiley Interscience, 1981).
  • the mixture of stereoisomers may be resolved by conventional methods such as microbial resolution, resolving the diastereomeric salts formed with chiral acids or chiral bases.
  • Chiral acids that can be employed may be tartaric acid, mandelic acid, lactic acid, camphorsulfonic acid, amino acids and the like.
  • Chiral bases that can be employed may be cinchona alkaloids, brucine or a basic amino group such as lysine, arginine and the like.
  • Isotopically labelled compounds of the present invention are useful in drug and/or substrate tissue distribution and target occupancy assays. For example, isotopically labelled compounds are particularly useful in SPECT (single photon emission computed tomography) and in PET (positron emission tomography).
  • the pharmaceutically acceptable salts forming a part of this invention may be prepared by treating the compound of formula (I) with 1-6 equivalents of a base such as sodium hydride, sodium methoxide, sodium ethoxide, sodium hydroxide, potassium t-butoxide, calcium hydroxide, calcium acetate, calcium chloride, magnesium hydroxide, magnesium chloride and the like.
  • Solvents such as water, acetone, ether, THF, methanol, ethanol, t-butanol, dioxane, isopropanol, isopropyl ether or mixtures thereof may be used.
  • Organic bases such lysine, arginine, methyl benzylamine, ethanolamine, diethanolamine, tromethamine, choline, guanidine and their derivatives may be used.
  • Acid addition salts whereever applicable may be prepared by treatment with acids such as tartaric acid, mandelic acid, fumaric acid, maleic acid, lactic acid, salicyclic acid, citric acid, ascorbic acid, benzene sulfonic acid, p-toluene sulfonic acid, hydroxynaphthoic acid, methane sulfonic acid, malic acid, acetic acid, benzoic acid, succinic acid, palmitic acid, oxalic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and the like in solvents such as water, alcohols, ethers, ethyl acetate, dioxane, DMF or a lower alkyl ketone such as acetone
  • Different polymorphs may be prepared by crystallization of compounds of general formula (I) under different conditions such as different solvents or solvent mixtures in varying proportions for recrystallization, various ways of crystallization such as slow cooling, fast cooling or a very fast cooling or a gradual cooling during crystallization. Different polymorphs may also be obtained by heating the compound, melting the compound and solidification by gradual or fast cooling, heating or melting under vacuum or under inert atmosphere, and cooling under either vacuum or inert atmosphere.
  • the various polymorphs may be identified by either one or more of the following techniques such as differential scanning calorimeter, powder X-ray diffraction, IR spectroscopy, solid probe NMR spectroscopy and thermal gravimetry.
  • compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers.
  • the active compounds of the invention may be formulated for oral, buccal, intranasal, parental (e.g., intravenous, intramuscular or subcutaneous) or rectal administration or a form suitable for administration by inhalation or insufflation.
  • “Therapeutically effective amount” is defined as 'an amount of a compound of the present invention that (i) treats or prevents the particular disease, condition, or disorder, (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of the particular disease, condition, or disorder described herein'.
  • the dose of the active compounds can vary depending on factors such as the route of administration, age and weight of patient, nature and severity of the disease to be treated and similar factors. Therefore, any reference herein to a pharmacologically effective amount of the compounds of general formula (I) refers to the aforementioned factors.
  • a proposed dose of the active compounds of this invention, for either oral, parenteral, nasal or buccal administration, to an average adult human, for the treatment of the conditions referred to above, is 0.1 to 200 mg of the active ingredient per unit dose which could be administered, for example, 1 to 4 times per day.
  • the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate).
  • binding agents e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g., lactose, microcrystalline cellulose or calcium phosphate
  • lubricants e.g., magnesium stearate, talc or silica
  • disintegrants e.g., potato starch or sodium
  • Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters or ethyl alcohol); and preservatives (e.g., methyl or propyl p-hydroxybenzoates or sorbic acid).
  • suspending agents e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats
  • emulsifying agents e.g., lecithin or acacia
  • non-aqueous vehicles e.g., almond oil, oily esters or ethyl alcohol
  • the composition may take the form of tablets or lozenges formulated in conventional manner.
  • the active compounds of the invention may be' formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g., sterile pyrogen- free water, before use.
  • the active compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
  • the active compounds of the invention are conveniently delivered in the form of an aerosol spray from a pressurized container or a nebulizer, or from a capsule using a inhaler or insufflator.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas and the dosage unit may be determined by providing a valve to deliver a metered amount.
  • the medicament for pressurized container or nebulizer may contain a solution or suspension of the active compound while for a capsule it preferably should be in the form of powder.
  • Capsules and cartridges for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
  • Aerosol formulations for treatment of the conditions referred to above e.g., migraine
  • each metered dose or "puff of aerosol contains 20 ⁇ g to 1000 ⁇ g of the compound of the invention.
  • the overall daily dose with an aerosol will be within the range 100 ⁇ g to 10 mg.
  • Administration may be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1, 2 or 3 doses each time.
  • Radio ligand binding assays for various 5-HT receptor sub-types are evaluated using standard radioligand binding assays and are described here. Radio ligand binding assays for various 5-HT receptor sub-types:
  • Receptor source Human recombinant expressed in HEK-293 cells
  • Radio ligand [3HJ-8-OH-DPAT (221 Ci/mmol) Final ligand concentration - [0.5 nM]
  • Receptor source Rat striatal membranes
  • Radioligand [ 125 l]lodocyanopindolol (2200 Ci/mmol)
  • Non-specific determinant Serotonin - [10 ⁇ M]
  • Reactions are carried out in 50 mM TRIS-HCI (pH 7.4) containing 60 ⁇ M (-) isoproterenol at 37°C for 60 minutes. The reaction is terminated by rapid vacuum filtration onto glass fiber filters. Radioactivity trapped onto the filters is determined and compared to control values in order to ascertain any interactions of test compound with the 5HT1B binding site.
  • Receptor source Human cortex
  • Radioligand [ 3 H] 5-Carboxamidotryptamine (20-70 Ci/mmol)
  • Non-specific determinant 5-Carboxamidotryptamine (5-CT) - [1.0 ⁇ M]
  • Reactions are carried out in 50 mM TRIS-HCI (pH 7.7) containing 4 mM CaCI 2 , 100 nM 8-OH-DPAT, 100 nM Mesulergine, 10 uM Pargyline and 0.1 % ascorbic acid at 25 °C for 60 minutes.
  • the reaction is terminated by rapid vacuum filtration onto glass fiber filters. Radioactivity trapped onto the filters is determined and compared to control values in order to ascertain any interactions of test compound with the cloned 5HTI D binding site.
  • Receptor source Human Cortex Radioligand : [ 3 H] Ketanserin (60-90 Ci/mmol) Final ligand concentration - [2.0 nM]
  • Non-specific determinant Ketanserin - [3.0 ⁇ M]
  • reaction is terminated by rapid vacuum filtration onto glass fiber filters.
  • Radioactivity trapped onto the filters is determined and compared to control values in order to ascertain any interactions of test compound with the 5HT 2A binding site.
  • Receptor source Pig choroid plexus membranes
  • Radioligand [ 3 H] Mesulergine (50-60 Ci/mmol)
  • Non-specific determinant Serotonin - [100 ⁇ M] Reference compound : Mianserin
  • Reactions are carried out in 50 mM TRIS-HCI (pH 7.7) containing 4 mM CaCI 2 and 0.1% ascorbic acid at 37 °C for 60 minutes. The reaction is terminated by rapid vacuum filtration onto glass fiber filters. Radioactivity trapped onto the filters is determined and compared to control values in order to ascertain any interactions of test compound with the 5HT2C binding site.
  • Receptor source N1 E-115 cells
  • Radioligand [ 3 H]-GR 65630 (30-70 Ci/mmol)
  • Non-specific determinant MDL-72222 - [1.0 ⁇ M]
  • Reactions are carried out in 20 mM HEPES (pH 7.4) containing 150 mM NaCl at 25 °C for 60 minutes. The reaction is terminated by rapid vacuum filtration onto glass fiber filters. Radioactivity trapped onto the filters is determined and compared to control values in order to ascertain any interactions of test compound with the 5HT 3 binding site.
  • Receptor source Guinea pig striatal membranes
  • Radioligand [ 3 H] GR-113808 (30-70 Ci/mmol) Final ligand concentration - [0.2 nM]
  • Non-specific determinant Serotonin (5-HT) - [30 ⁇ M]
  • Reference compound Serotonin (5-HT)
  • Reactions are carried out in 50 mM HEPES (pH 7.4) at 370C for 60 minutes. The reaction is terminated by rapid vacuum filtration onto glass fiber filters. Radioactivity trapped onto the filters is determined and compared to control values in order to ascertain any interactions of test compound with the 5HT 4 binding site.
  • Receptor source Human recombinant expressed in HEK 293 cells
  • Non-specific determinant Methiothepin mesylate - [1.0 ⁇ M]
  • Receptor source Human recombinant expressed in HEK293 cells
  • Radioligand [ 3 H]LSD (60-80 Ci/mmol)
  • Receptor source Human recombinant expressed in CHO cells
  • Non-specific determinant 5-Carboxamidotryptamine (5-CT) - [0.1 ⁇ M]
  • Reactions are carried out in 50 mM TRIS-HCI (pH 7.4) containing 10 mM MgCI 2 , 0.5 mM EDTA for 60 minutes at 37 °C.
  • the reaction is terminated by rapid vacuum filtration onto glass fiber filters. Radioactivity trapped onto the filters is determined and compared to control values in order to ascertain any interactions of test compound(s) with the cloned serotonin - 5HT 7 binding site.
  • reaction mixture was poured in cold water and the product was extracted in ethyl acetate (2 X 25 mL). The combined organic extracts were washed with water, followed by brine, dried over anhydrous sodium sulfate and the product was isolated by distillation of solvent under reduced pressure. The product usually was an oily compound, which was used as such for the next step.
  • sodium hydride 0.6 g; 0.0125 mole
  • sodium hydroxide 0.03 moles
  • potassium hydroxide 0.03 moles
  • 1-AcetyI-3-indoxyl (0.015 mole), was taken in three necked flask along with potassium carbonate (0.030 mole); tetrahydrofuran (ca 15 mL) and N,N- dimethylaminoethyl chloride (ca 15 % solution in toluene; 0.015 mole) and the mixture was refluxed for 3 hours. Another lot of N,N-dimethylaminoethyI chloride (ca 15 % solution in toluene; 0.015 mole) was added and the reaction mixture was refluxed for further 3 hours. The reaction mixture was cooled to 25 °C and filtered.
  • the filtrate was washed with water and brine; dried over sodium sulfate; organic solvens were removed under reduced pressure and the residue was purified by column chromatography, on silica gel; using hexane (100%) to triethylamine : ethyl acetate (2 : 98) gradual gradient as mobile phase, to obtain the compound of general formula (I) as thick oil, which was identified by IR, NMR and mass spectral analyses.
  • the final desired compound of general formula (X) can be further purified by preparation of their acid addition salts.
  • reaction mixture was poured onto the ice cooled water and extracted by Ethyl acetate (3 X 20 mL). The combined organic extract was washed with water and brine, dried over sodium sulphate and the volatiles were evaporated under vacuume to get the product as a thick dark oil.
  • the residue was purified by column chromatography, on silica gel; using hexane (100 %) to triethylamine : ethyl acetate (2 : 98) gradual gradient as mobile phase, to obtain the compound of general formula (I) as thick oil, which was identified by IR, NMR and mass spectral analyses.
  • the final desired compound of general formula (I) can be further purified by preparation of their acid addition salts. Melting range (°C) : Isolated as thick oil; Mass (m/z): 295.3(M+H) + .
  • Example - 4 [2-(1-(Benzyl)-2-methyl-1H-indol-3-yl)oxyethyl]dimethylamine Using essentially the general procedure described in example 1 and some non- critical variations, the above derivative was prepared. Melting range (°C) : Isolated as thick oil, Mass (m/z) : 309.3 (M+H) +
  • Example - 10 [2-(1-(2'-Bromobenzyl)-5-chloro-2-methyl-1H-indol-3- yl)oxyethyl]dimethylamine Using essentially the general procedure described in example 1 and some non- critical variations, the above derivative was prepared. Melting range (°C) : Isolated as thick oil ;Mass (m/z) : 421 , 423, 425 (M+H) +
  • Example - 12 [2-(1-(2'-Bromobenzyl)-5-bromo-1H-indol-3-yl)oxyethyl] dimethylamine Using essentially the general procedure described in example 1 and some non- critical variations, the above derivative was prepared.
  • Example - 23 [2-(1-(Benzoyl)-5,7-dibromo-2-phenyl-1H-indol-3- yl)oxyethyl]dimethylamine Using essentially the general procedure described in example 1 and some non- critical variations, the above derivative was prepared. Melting range (°C) : Isolated as thick oil; IR spectra (cm "1 ) :1680; Mass (m/z) : 541 , 543, 545 (M+H) +
  • Example - 24 [2-(1-(2'-Bromobenzyl)-5-methoxy-1H-indol-3-yl)oxyethyl] dimethylamine Using essentially the general procedure described in example 1 and some non- critical variations, the above derivative was prepared. Melting range (°C) : Isolated as thick oil Mass (m/z) : 403, 405 (M+H) +
  • Example - 25 [2-(1-(Benzoyl)-5-methoxy-1H-indol-3-yl)oxyethyl] dimethylamine Using essentially the general procedure described in example 1 and some non- critical variations, the above derivative was prepared. Melting range (°C) : Isolated as thick oil ;IR spectra (cm "1 ) :1680; Mass (m/z) : 339.4 (M+H) +
  • Example - 27 [2-(1-(2'-Bromobenzyl)-5-methoxy-2-phenyl-1H-indol-3- yl)oxyethyl]dimethylamine Using essentially the general procedure described in example 1 and some non- critical variations, the above derivative was prepared. Melting range (°C) : Isolated as thick oil ; Mass (m/z) : 479, 481 (M+H) +
  • Example - 29 [2-(1-(Benzoyl)-2-(4'-Methoxyphenyl)-1H-indol-3- yl)oxyethyl]dimethylamine Using essentially the general procedure described in example 1 and some non- critical variations, the above derivative was prepared. Melting range (°C) : Isolated as thick oil ; IR spectra (cm "1 ) :1680; Mass (m/z) : 415 (M+H) +

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne des 3-Aminoalcoxyindoles substitués représentés par les composés de la formule générale (I), leurs stéréoisomères, leurs radio-isotopes, leurs formes géométriques, leurs N-oxydes, leurs polymorphismes, leurs sels pharmaceutiquement acceptables, leurs solvates pharmaceutiquement acceptables, leurs métabolites bioactifs utiles ainsi que toute combinaison appropriée desdits éléments. Cette invention concerne également des procédés de préparation des composés représentés par la formule (I), de leurs stéréoisomères, de leurs radio-isotopes, de leurs formes géométriques, de leurs N-oxydes, de leurs polymorphismes, de leurs sels pharmaceutiquement acceptables, de leurs solvates pharmaceutiquement acceptables, de leurs métabolites bioactifs utiles ainsi que de toute combinaison appropriée desdits éléments. Cette invention concerne en outre diverses méthodes d'administration des composés représentés par la formule (I), autrement dit des formes dosifiées pharmaceutiquement acceptables, leur composition et leur utilisation dans le traitement ou le diagnostic.
PCT/IN2003/000371 2002-11-28 2003-11-25 N-arylalkyl-3-aminoalcoxyindoles et leur utilisation en tant que ligands des recepteurs 5-ht WO2004048331A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003292508A AU2003292508A1 (en) 2002-11-28 2003-11-25 N-arylalkyl-3-aminoalkoxyindoles and their use as 5-ht ligands

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN885MA2002 2002-11-28
IN885/MAS/02 2002-11-28

Publications (1)

Publication Number Publication Date
WO2004048331A1 true WO2004048331A1 (fr) 2004-06-10

Family

ID=32375368

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2003/000371 WO2004048331A1 (fr) 2002-11-28 2003-11-25 N-arylalkyl-3-aminoalcoxyindoles et leur utilisation en tant que ligands des recepteurs 5-ht

Country Status (2)

Country Link
AU (1) AU2003292508A1 (fr)
WO (1) WO2004048331A1 (fr)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7388024B2 (en) 2004-01-02 2008-06-17 Suven Life Sciences Limited Indeno[2,1A]indenes and isoindolo[2,1-A]indoles
WO2010032258A1 (fr) 2008-09-17 2010-03-25 Suven Life Sciences Limited Composés amines d'arylsulfonamide et leur utilisation en tant que ligands de 5-ht<sb>6</sb>
US7834037B2 (en) 2005-11-04 2010-11-16 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
US7923566B2 (en) 2005-08-16 2011-04-12 Suven Life Sciences Limited Alternative process for the preparation of losartan
US7964627B2 (en) 2007-10-26 2011-06-21 Suven Life Sciences Limited Amino arylsulfonamide compounds and their use as 5-HT6 ligands
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
WO2011083487A1 (fr) 2010-01-05 2011-07-14 Suven Life Sciences Limited Composés sulfones comme ligands du récepteur 5-ht6
US7998981B2 (en) 2005-08-12 2011-08-16 Suven Life Sciences Limited Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands
US8003670B2 (en) 2007-05-03 2011-08-23 Suven Life Sciences Limited Aminoalkoxy aryl sulfonamide compounds and their use as 5-HT6 ligands
US8318725B2 (en) 2008-09-17 2012-11-27 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US8470830B2 (en) 2007-01-08 2013-06-25 Suven Life Sciences Limited 5-(heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds and their use as 5-HT6 ligands
US8697730B2 (en) 2007-10-26 2014-04-15 Panmira Pharmaceuticals, Llc 5-lipoxygenase activating protein (FLAP) inhibitor
US8772495B2 (en) 2008-05-23 2014-07-08 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein inhibitor
JP2014139252A (ja) * 2008-06-27 2014-07-31 Novartis Ag 有機化合物
KR101534136B1 (ko) * 2013-06-11 2015-07-07 이화여자대학교 산학협력단 인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 5-ht6 수용체 관련 질환의 예방 또는 치료용 약학적 조성물
CN104829568A (zh) * 2015-05-12 2015-08-12 广州中医药大学 一种2-苯基-苯骈五元杂环类化合物及其衍生物的医药应用
CN104829569A (zh) * 2015-05-12 2015-08-12 广州中医药大学 一种2-苯基-苯骈五元杂环类化合物及其衍生物的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2058140A1 (de) * 1970-11-26 1972-05-31 Novo Terapeutisk Labor As Indol-Derivate
DE2065321A1 (de) * 1969-05-27 1973-05-24 Novo Terapeutisk Labor As Indol-derivate
EP0429984A2 (fr) * 1989-11-17 1991-06-05 Nisshin Flour Milling Co., Ltd. Dérivés d'indole
WO2000046199A2 (fr) * 1999-02-05 2000-08-10 Astrazeneca Ab Composes chimiques
WO2001017963A2 (fr) * 1999-09-07 2001-03-15 Pharmacia & Upjohn Company Aminoalcoxy carbazoles permettant de traiter des maladies du systeme nerveux central

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2065321A1 (de) * 1969-05-27 1973-05-24 Novo Terapeutisk Labor As Indol-derivate
DE2058140A1 (de) * 1970-11-26 1972-05-31 Novo Terapeutisk Labor As Indol-Derivate
EP0429984A2 (fr) * 1989-11-17 1991-06-05 Nisshin Flour Milling Co., Ltd. Dérivés d'indole
WO2000046199A2 (fr) * 1999-02-05 2000-08-10 Astrazeneca Ab Composes chimiques
WO2001017963A2 (fr) * 1999-09-07 2001-03-15 Pharmacia & Upjohn Company Aminoalcoxy carbazoles permettant de traiter des maladies du systeme nerveux central

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7388024B2 (en) 2004-01-02 2008-06-17 Suven Life Sciences Limited Indeno[2,1A]indenes and isoindolo[2,1-A]indoles
US7998981B2 (en) 2005-08-12 2011-08-16 Suven Life Sciences Limited Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands
US7923566B2 (en) 2005-08-16 2011-04-12 Suven Life Sciences Limited Alternative process for the preparation of losartan
US8710081B2 (en) 2005-11-04 2014-04-29 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8841295B2 (en) 2005-11-04 2014-09-23 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US7834037B2 (en) 2005-11-04 2010-11-16 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US8470830B2 (en) 2007-01-08 2013-06-25 Suven Life Sciences Limited 5-(heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds and their use as 5-HT6 ligands
US8003670B2 (en) 2007-05-03 2011-08-23 Suven Life Sciences Limited Aminoalkoxy aryl sulfonamide compounds and their use as 5-HT6 ligands
CN101835748B (zh) * 2007-10-26 2012-11-14 苏文生命科学有限公司 氨基芳基磺胺化合物及其作为5-ht6配体的用途
US7964627B2 (en) 2007-10-26 2011-06-21 Suven Life Sciences Limited Amino arylsulfonamide compounds and their use as 5-HT6 ligands
US8697730B2 (en) 2007-10-26 2014-04-15 Panmira Pharmaceuticals, Llc 5-lipoxygenase activating protein (FLAP) inhibitor
US8772495B2 (en) 2008-05-23 2014-07-08 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein inhibitor
JP2014139252A (ja) * 2008-06-27 2014-07-31 Novartis Ag 有機化合物
US8404720B2 (en) 2008-09-17 2013-03-26 Suven Life Sciences Limited Aryl sulfonamide amine compounds and their use as 5-HT6 ligands
WO2010032258A1 (fr) 2008-09-17 2010-03-25 Suven Life Sciences Limited Composés amines d'arylsulfonamide et leur utilisation en tant que ligands de 5-ht<sb>6</sb>
US8318725B2 (en) 2008-09-17 2012-11-27 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
WO2011083487A1 (fr) 2010-01-05 2011-07-14 Suven Life Sciences Limited Composés sulfones comme ligands du récepteur 5-ht6
KR101534136B1 (ko) * 2013-06-11 2015-07-07 이화여자대학교 산학협력단 인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 5-ht6 수용체 관련 질환의 예방 또는 치료용 약학적 조성물
CN104829568A (zh) * 2015-05-12 2015-08-12 广州中医药大学 一种2-苯基-苯骈五元杂环类化合物及其衍生物的医药应用
CN104829569A (zh) * 2015-05-12 2015-08-12 广州中医药大学 一种2-苯基-苯骈五元杂环类化合物及其衍生物的应用

Also Published As

Publication number Publication date
AU2003292508A1 (en) 2004-06-18

Similar Documents

Publication Publication Date Title
US7718690B2 (en) N-arylsulfonyl-3-aminoalkoxyindoles
WO2004048331A1 (fr) N-arylalkyl-3-aminoalcoxyindoles et leur utilisation en tant que ligands des recepteurs 5-ht
CA2507923C (fr) Indoles tetracycliques 3-substitues a affinite pour le recepteur de serotonine
CA2490254C (fr) Nouveaux indoles tetracycliques arylsulfonyle ayant une affinite du recepteur de la serotonine et utiles comme agents therapeutiques, leur procede de preparation et compositions pharmaceutiques les contenant
US7297711B2 (en) Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
EP1517909A2 (fr) Nouveaux indols d&#39;arylcarbonyle tetracycliques presentant une affinite pour le recepteur de la serotonine utilises comme agents therapeutiques, procede de preparation et compositions pharmaceutiques les contenant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP